Baseline characteristics of the patients
| Variable | Number of patients, n/value | Percentage (%) | irAE group and non-irAE group | |
|---|---|---|---|---|
| χ2 | P | |||
| Gender | 0.044 | 0.834 | ||
| Male | 81 | 77.14 | ||
| Female | 24 | 22.86 | ||
| Age, years | 2.308 | 0.129 | ||
| Median | 61 | |||
| Scope | 24–84 | |||
| ECOG PS | 3.137 | 0.077 | ||
| 0 | 17 | 16.19 | ||
| 1 | 88 | 83.81 | ||
| BMI | 0.054 | 0.816 | ||
| Mean value | 23.55 ± 0.36 (95% CI 22.83–24.27) | |||
| Scope | 15.8–31.2 | |||
| Tumor types | ||||
| Lung cancer | 52 | 49.52 | ||
| Melanoma | 15 | 14.29 | ||
| Esophageal cancer | 11 | 10.48 | ||
| Liver cancer | 9 | 8.57 | ||
| Urothelial carcinoma | 8 | 7.62 | ||
| Gastric cancer | 5 | 4.76 | ||
| Other types of tumors | 5 | 4.76 | ||
| Distant metastasis | 2.638 | 0.104 | ||
| Non- | 65 | 61.90 | ||
| One or more- | 40 | 38.10 | ||
| Prior therapy | ||||
| Chemotherapy | 67 | 63.81 | ||
| Radiotherapy | 22 | 20.95 | ||
| Targeted therapy | 8 | 7.62 | ||
| Immunotherapy | 3 | 2.86 | ||
| Other therapies (interferon therapy, interventional/radiofrequency ablation therapy) | 9 | 8.57 | ||
| Treatment lines | 3.193 | 0.074 | ||
| First-line | 28 | 26.67 | ||
| Non first-line | 77 | 73.33 | ||
| Treatment regimen | ||||
| Anti-PD-1 | 82 | 78.10 | ||
| Anti-PD-L1 | 13 | 12.38 | ||
| Anti-PD-1 + anti-CTLA-4 | 10 | 9.52 | ||
irAEs, immune-related adverse events; PD-1, programmed cell death protein-1; PD-L1, programmed cell death ligand-1; CTLA-4, cytotoxic T-lymphocyte-associated protein-4; ECOG PS, Eastern Cooperative Oncology Group performance status.